Новые возможности применения фторхинолонов в пульмонологии

1. Hooper D., Rubinstein Е., eds. Quinolone antimicrobial agents. 3-rd ed. AMS Press; 2003.

2. Brueggemann A., Coffman S., Rhomberg P. et al. Fluoroquinolone resistance in streptococcus pneumoniae in the United States since 1994-1995. Antimicrob. Agents Chemother. 2002; 46: 680-688.

3. Song J.H., Jung S.I., Ко K.S. et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob. Agents Chemother. 2004; 48: 2101-2107.

4. Ho P., Tse W., Tsang K. et al. Risk factors for acquisition of lev-ofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin. Infect. Dis. 2001; 341: 1546-1548.

5. Niederman AL, Mandell L., Anzueto A. et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-1754.

6. Stratchounski L.S., Kozlov R.S., Sivaja O.V., Poupard J.A. Antimicrobial resistance in Russia among Streptococcus pneumoniae causing community-acquired respiratory tract infections: PEHASus-I surveillance program, 2001-2002. In: Proceedings of 41-st Annual meeting of the IDSA, 9-12 October, 2003. San Diego; 2003. Abstr. 207.

7. Stratchounski L.S., Tarasov A.A., Kozlov R.S. et al. Antimicrobial susceptibility of Streptococcus pneumoniae isolated from adults with acute sinusitis in 3 Russian centers. In: Proceedings of 14-th ECCMID, 1-4 May 2004. Prague; 2004. Abstr. PI 147.

8. Grudinina S.F., Sidorenko S.F., Rezvan S.P. et al. Five year surveillance of Streptococcus pneumoniae resistance in Moscow, Russia. In: Proceedings of 43-rd ICAAC, 14-17 September 2003. Chicago; 2003. Abstr. C2-945.

9. Martynova A.V., Turcutyuicov V.B. Epidemiology of antibiotic-resistant Streptococcus pneumoniae strains in Far East Russia. Int. J. Antimicrob. Agents 2004; 23: 641-643.

10. Nuermberger E., Bishai W. Management of community-acquired pneumonia caused by drug-resistant Streptococcus pneumoniae. In: Gillespie S., ed. Management of multiple drug-resistant infections. Totowfa: Humana Press; 2004. 3-29.

11. Howe R., MacGovan A. Quinolones. In: Cohen G., Powderly W., eds. /nfectious diseases. 2-nd ed. Amsterdam: Elsevier Ltd.; 2004. 1827-1836.

12. Wise R. Maximizing efficacy and reducing the emergence of resistance. J. Antimicrob. Chemother. 2003; 51 (suppl. 1): 37-42.

13. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infectious. Curr. Opin. Infect. Dis. 2001; 14: 165-172.

14. Zhanel G., Walters M., Karlowsky J. et al. Activity of free (unbound) fluoroquinolone serum concentrations versus multi-drug resistant Streptococcus pneumoniae using an in vitro pharmacodynamic model. In: Proceedings of the 40-th ICAAC, 17—20 September 2000. Toronto; 2000. Abstr. A-292.

15. Wright D., Brown G., Peterson AL, Rotschafer J. Application of fluoroquinolones pharmacodynamics. J. Antimicrob. Chemother. 2000; 46: 669-683.

16. Data on file. Bristol-Myers Squibb.

17. Data on file. Oscient Pharmaceuticals.

18. Grohs P., Houssaye S., Aubert A. et al. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci and Enterococcus faecalis compared to those of six other quinolones. Antimicrob. Agents Chemother. 2003; 47: 3542-3547.

19. Perez-Vazquez M., Roman F., Aracil B. et al. In vitro activities of garenoxacin (BMS-284756) against Haemophilus influenzae isolates with different fluoroquinolone susceptibilites. Antimicrob. Agents Chemother. 2003; 47: 3539-3541.

20. Christiansen K.J., Bell J.M., Turnidge J.D., Jones R.N. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001. Antimicrob. Agents Chemother. 2004; 48: 2049-2055.

21. Liebetrau A., Rodloff A.C., Behra-Miellet J., Dubreuil L. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob. Agents Chemother. 2003; 47: 3667-3671.

22. Blondeau J.M., Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert. Opin. Pharmacother. 2004; 5: 1117-1152.

23. Appelbaum P.C., Gillespie S.H., Burley C.J., Tillotson G.S. Antimicrobial selection for community-acquired lower respiratory tract infections in 21st century: a review of gemifloxacin. Int. J. Antimicrob. Agents 2004; 23: 533-546.

24. Allen A., Bygate E., Oliver S. et al. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother. 2000; 44: 1604-1608.

25. Leophonte P., File T., Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir. Med. 2004; 98: 708-720.

26. Sethi S., Fogarty C., Fulambarker A. A randomized, doubleblind study comparing 5 days oral gemifloxacin with 7 days oral ievofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med. 2004; 98: 697-707.

27. Ball P., Mandell L., Patou G. et al. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. Int. J. Antimicrob. Agents 2004; 23: 421-429.

28. Dunbar L., Wunderink R., Habib M. et al. High-dose, short-course ievofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 2003; 37: 752-760.

29. Karlowsky J., Thornsberry C, Critchley I. et al. Susceptibilities to ievofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: Results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob. Agents Chemother. 2003; 47: 1790-1797.

30. Yu V., Greenberg R., Zadeikis N. et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125: 2135-2139. "

31. Dunbar L., Khashab M., Kahn J. et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr. Med. Res. Opin. 2004; 20: 555-563.

32. Антипин A.H., Арсенин С.Л., Прилуцкая M.A., Белобородов В.Б. Особенности диагностики и лечения внебольничной пневмонии, вызванной Legionella pneumophila. Рос. мед. вести 2004; (2): 23-31.

33. West AL, Boulanger В., Fogarty С. et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin. Ther. 2003; 25: 485-506.

34. Croom К., Goa L. Levofloxacin. A review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63: 2769-2802.

35. Nightingale C., Grant £., Quintiliani R. Pharmacodynamics and pharmacokinetics of levofloxacin. Chemotherapy 2000; 46 (suppl. 1): 6-14.

36. Ball P. Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. Curr. Ther. Res. 2003; 64: 646-661.

37. Kahn J. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001; 47 (suppl. 3): 32-37.